Viridian Therapeutics Inc (NASDAQ:VRDN) traded at $15.85 at close of the session on Tuesday, February 18 and made a downward move of -3.35% on its previous day’s price.
Viridian Therapeutics Inc has a market cap of $1.26 billion and is expected to release its quarterly earnings report in March.
The median projection represents growth adding up to -32.26% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 314.57k, or 0.18% up from figures reported last year.
On the other hand, looking at the outlook for the VRDN stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 11 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Viridian Therapeutics Inc (VRDN) stock as a Hold, while 10 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -13.91% off its SMA20 and -15.94% from its 50-day simple moving average. The RSI (14) is pointing at 31.14 while the volatility over the past week is 5.45% and jumps to 5.27% over the past one month. The beta value is 1.05, while the average true range (ATR) is currently pointing at 1.00. The average price target for the stock over the next 12 months is $22, with the estimates having a low of $19 and a high of $28. These price ends are -19.87% and -76.66% off the current price level respectively, although investors could be excited at the prospect of a -38.8% if the VRDN share price touches on the median price of $22.
